跳至主要内容
临床试验/NCT04955704
NCT04955704Unknown不适用

Performance Study for InferRead CT Pneumonia.AI

Infervision0 个研究点目标入组 423 人开始时间: 2021年9月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
423
主要终点
Primary Endpoint

研究概览

简要总结

A retrospective, blineded, multicenter study of the InferRead CT Pneumonia.AI to evaluate the performance in identifying non-contrast chest CT scans containing pneumonia findings.

详细描述

This is a retrospective, blinded, multicenter study for the InferRead CT Pneumonia.AI. The primary endpoint will evaluate the software's performance in identifying non-contrast chest CT scans containing pneumonia. It will evaluate InferRead CT Pneumonia.AI in terms of sensitivity and specificity with respect to a ground truth, as established by trained thoracic radiologists, in the detection of penumonia. In addition, the study will compare time to notification for the InferRead CT Pneumonia.AI software with respect to the time to notification for the standard of care as established from available radiological reports.

  1. To evaluate the performance of InferRead CT Pneumonia.AI.
  2. To evaluate the effect of different factors such as CT manufacturer, CT scanning protocols and patient characteristics on the performance of InferRead CT Pneumonia.AI

研究设计

研究类型
Observational
观察模型
Other
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Non-contrast chest CT DICOM scans
  • •Contains both lung lobes
  • •Slice thickness is less than 3 mm.

排除标准

  • •Incomplete scan or corrupted scan
  • •Irregular scanning, increased intrapulmonary density due to insufficient inspiration, and respiratory artifacts affecting the physician's judgment.
  • •Altered or absent lung morphology in the postoperative patient.

结局指标

主要结局

Primary Endpoint

时间窗: 1/1/2022 - 2/28/2022

1. The Sensitivity (SE) of InferRead CT Pneumonia.AI is higher than 0.80. H0: YSE ≤ 0.80 HA: YSE \> 0.80 2. The Specificity (SP) of InferRead CT Pneumonia.AI is higher than 0.80. H0: YSP ≤ 0.80 HA: YSP \> 0.80

次要结局

  • Secondary Endpoint(1/1/2022 - 2/28/2022)

研究者

发起方
Infervision
申办方类型
Industry
责任方
Sponsor

相似试验